Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment challenges in hypercholesterolemia

P Pauciullo1, M Mancini

  • 1Dipartimento di Medicina Clinica e Sperimentale, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy.

Cardiovascular Drugs and Therapy
|November 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the traditional interpretation of Mediterranean diet.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2003
Same author

High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.

Annals of hematology·2003
Same author

Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

Leukemia·2003
Same author

A prototype of an adjustable advanced reciprocating gait orthosis (ARGO) for spinal cord injury (SCI).

Spinal cord·2003
Same author

C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.

Leukemia·2003
Same author

Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines.

Rheumatology (Oxford, England)·2002
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
Same journal

Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.

Cardiovascular drugs and therapy·2026
See all related articles

Cholesterol-lowering drugs significantly reduce coronary heart disease (CHD) risks and prolong life, with benefits proportional to cholesterol reduction. Treatment decisions for hypercholesterolemia are based on LDL levels and overall CHD risk.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Preventive Cardiology

Background:

  • High plasma cholesterol is a significant risk factor for coronary heart disease (CHD).
  • Lipid-lowering drug therapy has demonstrated efficacy in reducing CHD morbidity and mortality.
  • Clinical benefits correlate with the extent of plasma cholesterol reduction.

Purpose of the Study:

  • To review the evidence supporting cholesterol-lowering drug treatment for primary and secondary prevention of CHD.
  • To discuss the mechanisms underlying the clinical benefits of lipid-lowering therapies.
  • To outline treatment selection criteria for hypercholesterolemia.

Main Methods:

  • Analysis of primary and secondary prevention trials involving cholesterol-lowering drugs.

Related Experiment Videos

  • Review of data on atherosclerosis regression and progression.
  • Examination of mechanisms beyond lipid reduction, including effects on macrophages, vasodilation, and thrombogenesis.

    • Main Results:

    • Cholesterol-lowering drug treatment significantly reduces CHD risk and improves survival.
    • Clinical benefits are proportional to the percentage reduction in plasma cholesterol.
    • Mechanisms include reduced atherogenicity, improved vasodilation, and decreased thrombogenesis.

    Conclusions:

    • Lipid-lowering therapy is crucial for patients with CHD or high CHD risk, including those with subclinical atherosclerosis.
    • Treatment selection considers LDL levels, global CHD risk, efficacy, safety, tolerability, and cost-effectiveness.
    • Combination therapy may be necessary for refractory hypercholesterolemia; prevention strategies are cost-effective.